Issam Ben-Sahra

Research Fellow

Department of Genetics and Complex Diseases

Department of Genetics and Complex Diseases

Building 2, Room 131
655 Huntington Avenue
Boston, Massachusetts 02115


Ph.D. 2010, University of Sophia Antipolis, Nice, France

Research Interests

Issam is interested in understanding the impact of mTOR-stimulated metabolic pathways on the properties of cells and tumors with specific upstream oncogenic events.  He is focused on revealing how metabolic changes common to tumor cells can differentiate them from their tissue of origin, with a focus on revealing novel therapeutic opportunities.


Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand Brustel Y, Auberger P, Tanti JF, Giorgetti Peraldi S, Bost F. Metformin, independent of AMPK, induces mTOR inhibition and cell cycle arrest through REDD1. Cancer Research 2011 May 3

Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther. 2010 May;9(5):1092-9.

Ben Sahra I, Tanti JF, Bost F. The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK dependent apoptosis in prostate cancer cells. Autophagy 2010 Jul 21;6(5)

Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, LeMarchand-Brustel Y, Giorgetti-Peraldi S, Cormont M, Bertolotto C, Deckert M, Auberger P, Tanti JF, Bost F. Targeting cancer cell metabolism: The combination of metformin and 2-deoxyglucose induces p53 dependent apoptosis in prostate cancer cells. Cancer Research 2010 Mar 15;70(6):2465-75

Robert G, Ben Sahra I, Puissant A, Colosetti P, Belhacene N, Gounon P, Hofman P, Bost F, Cassuto JP, Auberger P. Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death. PLoS One 2009 Nov 18;4(11):e7889.

Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y, Bost F. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008 Jun 5;27(25):3576-86.